

## CURRENT REPORT 16/2026

June 25<sup>th</sup>, 2026

### Appointment of Supervisory Board Members of Ryvu Therapeutics S.A. for a new term of office

The Management Board of Ryvu Therapeutics S.A. with its registered office in Krakow, Poland ("Company", "Issuer") hereby informs that the Ordinary General Meeting of the Company appointed, effective June 25th, 2026, the Supervisory Board Members of the Company for a new term of office, in the following composition:

1. **Mr. Piotr Romanowski** - Chairman of the Supervisory Board of the Company;
2. **Mr. Tadeusz Wesółowski** – Vice- Chairman of the Supervisory Board of the Company;
3. **Mr. Rafał Chwast** - Member of the Supervisory Board of the Company;
4. **Mr. Scott Z. Fields** - Member of the Supervisory Board of the Company;
5. **Mr. Peter Smith** - Member of the Supervisory Board of the Company.

Information on the appointed Supervisory Board Members:

#### **Mr. Piotr Romanowski**

He has many years of experience in investment advisory in biotechnology, advanced technologies and financial services. He serves as Chairman of the Supervisory Board of Ryvu Therapeutics S.A. Dr. Romanowski has over 20 years of experience in strategic management consulting, gained as Partner at McKinsey & Company and PwC, where he specialized in mergers and acquisitions strategy in financial services, oil and gas, the pharmaceutical sector and healthcare. Mr. Piotr Romanowski was also a member of the Management Board of Bank Millennium S.A., responsible for Corporate and Investment Banking. He holds a PhD in molecular biology from the University of Cambridge and a PhD in medical sciences, specializing in cancer genetics, from the Medical University of Gdańsk.

Mr. Piotr Romanowski, according to the statement submitted to the Company, is not entered in the Register of Insolvent Debtors maintained pursuant to the Act on the National Court Register and does not conduct any activities competitive to Ryvu Therapeutics S.A., does not participate in a company competitive to Ryvu Therapeutics S.A. as a partner in a civil-law partnership, partnership or capital company, and does not participate in any other legal person competitive to Ryvu Therapeutics S.A. as a member of its governing body.

#### **Mr. Tadeusz Wesółowski**

He obtained a PhD in technical sciences from the Warsaw University of Technology. After graduation, he continued his academic work at the university as an assistant professor. In 1990, he established and managed PROSPER, which forms part of the NEUCA S.A. capital group. He has repeatedly advised on and participated in creating new ventures in the pharmaceutical market.

Mr. Tadeusz Wesolowski, according to the statement submitted to the Company, is not entered in the Register of Insolvent Debtors maintained pursuant to the Act on the National Court Register and does not conduct any activities competitive to Ryvu Therapeutics S.A., does not participate in a company competitive to Ryvu Therapeutics S.A. as a partner in a civil-law partnership, partnership or capital company, and does not participate in any other legal person competitive to Ryvu Therapeutics S.A. as a member of its governing body.

**Mr. Rafał Chwast**

He is a graduate of the Krakow University of Economics in accounting and AGH University of Science and Technology in Krakow in computer science. From 1997 to 2007, he served as Vice-President of the Management Board and Chief Financial Officer of Comarch. He was responsible for financial supervision over the group companies, raising capital through the stock exchange for Comarch and Interia.pl, and the acquisition of CDN. From 2003 to 2006, he also served as President of the Polish Association of Listed Companies and was a member of the Capital Market Council operating under the Prime Minister.

Mr. Rafał Chwast, according to the statement submitted to the Company, is not entered in the Register of Insolvent Debtors maintained pursuant to the Act on the National Court Register and does not conduct any activities competitive to Ryvu Therapeutics S.A., does not participate in a company competitive to Ryvu Therapeutics S.A. as a partner in a civil-law partnership, partnership or capital company, and does not participate in any other legal person competitive to Ryvu Therapeutics S.A. as a member of its governing body.

**Mr. Scott Z. Fields**

Scott Z. Fields, M.D., is a medical oncologist/hematologist with more than 30 years of experience in clinical drug development. Dr. Fields currently serves as Chief Medical Officer at NeoTX Therapeutics.

Prior to joining NeoTX, Dr. Fields was the Global Head of Development for Oncology at Bayer Pharmaceuticals. In this role, he was responsible for early and late-stage development, including several novel oncology medicines across the platforms for targeted therapies/precision medicine, antibody-drug/alpha radiation conjugates and novel Immuno-Oncology agents, such as Darolutamide (Androgen Receptor inhibitor for prostate cancer), Larotrectinb (NTRK inhibitor – tissue agnostic), Xofigo (Radium223 – alpha particle emitter for prostate cancer), Copanlisib (PI3K inhibitor for lymphoma) and Regorafenib (multi-kinase inhibitor for liver, colon and GIST). Prior to his position at Bayer, Dr. Fields held senior positions at Vertex Pharmaceuticals, SmithKline Beecham, Amgen, Eisai, and Arno Therapeutics and helped bring over a dozen drugs to market. He also practiced oncology/hematology and transplant medicine in academic settings.

Dr. Fields received his medical degree from SUNY Downstate Medical Center in New York, followed by training in internal medicine and hematology, and oncology at Columbia University Medical Center.

Mr. Scott Z. Fields, according to the statement submitted to the Company, is not entered in the Register of Insolvent Debtors maintained pursuant to the Act on the National Court Register and does not conduct any activities competitive to Ryvu Therapeutics S.A., does not participate in a company competitive to Ryvu Therapeutics S.A. as a partner in a civil-law partnership, partnership or capital

company, and does not participate in any other legal person competitive to Ryvu Therapeutics S.A. as a member of its governing body.

**Mr. Peter Smith**

Peter Smith, Ph.D., is a pharmaceutical executive with over 20 years of experience in drug discovery and development. He has proven experience in company building and the discovery and development of new therapeutics for various diseases of unmet need. Dr. Smith is Co-Founder and currently Chief Executive Officer of Remix Therapeutics. He also serves as Entrepreneur-In-Residence at Atlas Venture, where he is Co-founder and Acting CSO of Amplify Medicine, as well as an advisor to other Atlas portfolio companies.

Previously, he served as CSO at H3 Biomedicine, where his team introduced three molecules into the clinic with precision medicine approaches to treat various cancers. Prior to H3 Biomedicine, he was at Millenium/Takeda, where he focused on oncology drug discovery and early clinical development.

Dr. Smith received his PhD from Newcastle University and completed post-doctoral training at Dana Farber Cancer Institute.

*Disclaimer: This English language translation has been prepared solely for the convenience of English speaking readers. Despite all the efforts devoted to this translation, certain discrepancies, omissions or approximations may exist. In case of any differences between the Polish and the English versions, the Polish version shall prevail. Ryvu Therapeutics S.A., its representatives and employees decline all responsibility in this regard.*

**Legal basis:** Article 56.1.2 of the Act on Offerings

**Representatives of the Issuer:**

- Paweł Przewięźlikowski – President of the Management Board
- Krzysztof Brzózka - Vice-President of the Management Board